Decoy Therapeutics, a biotech company developing broad-spectrum antiviral drugs, announced that CEO Rick Pierce will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 10, 2026. The company is advancing its lead antiviral candidates targeting multiple respiratory viruses using its AI-driven IMP³ACT™ platform. This presentation offers investors insight into Decoy's innovative approach to viral treatment and its progress toward clinical trials.
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
